Market cap
$34m
End-of-day close multiplied by current shares on issue.
ARB · NZX
ArborGen Holdings is an NZX-listed primary industries / forestry genetics company with HY22 - FY26 of published result briefings.
Snapshot
FY26, released 29 May 2026
| Metric | Value | Change |
|---|---|---|
| Revenue | $68.2m | ↑ +7.9% |
| Operating profit | -$0.5m | ↓ -104.5% |
| NPAT | -$7.5m | ↑ +65.1% |
| Operating cash flow | $3.7m | ↑ +37.0% |
| OCF / Operating profit % | -740.0% | ↓ -764.1pp |
| Net debt | $25.1m | ↑ +20.1% |
| Net debt / Operating profit | n/m | — |
| ROE % | -6.3% | ↑ +11.0pp |
| PBT | -$3.4m | ↑ +84.9% |
| FCF pre-lease | -$0.4m | ↑ +92.2% |
Source: latest published briefing (FY26, released 29 May 2026). Change compares against the prior equivalent period: FY25, released 30 May 2025.
Valuation
A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.
The latest close and share count context for the market price.
Market cap
$34m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.01
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not meaningful when recent EBITDA is negative.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
0.29x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Daily closes use the full available width, with hover and touch readouts against real observations. Expand opens the chart at reading size.
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Chat
Ask follow-up questions about ArborGen Holdings's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Longitudinal view
The latest period is shown first.
| Metric | FY2612 MONTHS29 May 2026 | HY266 MONTHS26 November 2025 | FY2512 MONTHS30 May 2025 | FY2412 MONTHS30 May 2024 | HY246 MONTHS13 December 2023 | FY2312 MONTHS30 May 2023 | HY236 MONTHS29 November 2022 | FY2212 MONTHS30 May 2022 | HY226 MONTHS24 November 2021 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $68.2m | $14.2m | $63.2m | $67.7m | $13.2m | $56.1m | $7.4m | $47.6m | $4.6m | Chart |
| Revenue growth % | 7.9% | 7.6% | -6.6%Outside range low revenue growth. -6.6%; 3-period range 7.9% to n/m. Revenue growth: -6.6%, below normal range; 3-period mean 382.7%, range 7.9%n/m. | 20.7% | 78.4%Outside range high revenue growth. 78.4%; 3-period range -61.3% to 60.9%. Revenue growth: 78.4%, above normal range; 3-period mean 2.4%, range -61.3%-60.9%. | n/m | 60.9% | — | -61.3%Outside range low revenue growth. -61.3%; 3-period range 7.6% to 78.4%. Revenue growth: -61.3%, below normal range; 3-period mean 49.0%, range 7.6%-78.4%. | Chart
|
| Operating profit | -$0.5m | -$2.1m | $11.2m | -$0.2m | -$0.5m | $10.3m | -$0.9m | -$1.3m | $0m | Chart |
| Operating profit margin % | -0.7%Outside range low ebitda margin. 16.8%; 3-period range 17.7% to 21.2%. EBITDA margin: 16.8%, below normal range; 3-period mean 19.1%, range 17.7%-21.2%. | -14.8% | 17.7% | -0.3% | -3.8% | 18.4% | -12.2% | -2.7%Outside range high ebitda margin. 21.2%; 3-period range 16.8% to 18.4%. EBITDA margin: 21.2%, above normal range; 3-period mean 17.6%, range 16.8%-18.4%. | 0.0% | Chart
|
| PBT | -$3.4m | -$2m | -$22.5m | -$1.6m | -$1.5m | $0.9m | -$1.6m | -$3m | -$0.9m | Chart |
| NPAT | -$7.5m | -$0.6m | -$21.5m | -$0.2m | -$0.1m | -$2.5m | -$1.6m | $1.7m | $0.1m | Chart |
| NPAT growth % | — | — | — | — | — | — | — | — | -97.5% | — |
| Operating cash flow | $3.7m | -$5.4m | $2.7m | $11.7m | $2.1m | $6.5m | -$2.4m | $7.5m | $0.1m | Chart |
| OCF / Operating profit % | -740.0% | 257.1% | 24.1%Outside range low ocf / ebitda cash conversion. 24.1%; 3-period range 32.2% to 74.3%. OCF / EBITDA cash conversion: 24.1%, below normal range; 3-period mean 56.5%, range 32.2%-74.3%. | n/m | -420.0% | 63.1% | 266.7% | -576.9%Outside range high ocf / ebitda cash conversion. 74.3%; 3-period range 24.1% to 63.1%. OCF / EBITDA cash conversion: 74.3%, above normal range; 3-period mean 39.8%, range 24.1%-63.1%. | — | Chart
|
| FCF pre-lease | -$0.4m | — | -$5.1m | $5.1m | — | — | -$4.8m | $6m | — | Chart |
| ROE % | -6.3% | -0.5% | -17.3%Unprecedented low roe. -17.3%; 4-period range -6.3% to 1.1%. ROE: -17.3%, unprecedented low; 4-period mean -1.8%, range -6.3%-1.1%. | -0.1% | -0.1% | -1.7% | -1.1% | 1.1%Outside range high roe. 1.1%; 4-period range -17.3% to -0.1%. ROE: 1.1%, above normal range; 4-period mean -6.3%, range -17.3%--0.1%. | 0.1% | Chart
|
| Net debt | $25.1m | $30.4m | $20.9m | $14.4m | $16.7m | $13m | $17.5m | -$41.9m | — | Chart |
| Net debt / Operating profit | n/m | n/m | 1.87x | n/m | n/m | 1.26x | n/m | 32.23x | — | Chart |
| Debtor days | 64 | n/m | n/m | 68 | n/m | n/m | — | n/m | n/m | Chart |
| Inventory days | 225 | n/m | 222 | 294 | n/m | 206 | n/m | 209 | n/m | Chart |
| Total assets | $174.4m | $187.2m | $175.5m | $197.3m | $201.8m | $199.8m | $191.3m | $192.1m | $202.8m | Chart |
Reference: annolyse.ai/companies/arb
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Reported revenue across covered periods.
Like-period revenue growth where comparable.
Company-specific earnings measure where disclosed.
EBITDA-equivalent margin where revenue and earnings are source-backed.
Statutory profit after tax.
Cash generated from operations.
Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.
Cash conversion against earnings.
Operating cash flow less capex before leases.
Return on equity.
Borrowings less cash; negative values indicate net cash.
Leverage ratio, suppressed where earnings are not meaningful.
Receivables days where the working-capital inputs are source-backed.
Inventory days where the working-capital inputs are source-backed.
Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.
The setup & the reality
The latest result is checked against what the prior briefing said to watch.
Historical setup
Previous analysisHY26Result releasedAnnolyse analysis published
From Pre-lease FCF fell to NZ$-7.2m as gross borrowings rose 61.9% to NZ$34.0m
No forward targets or guidance figures are supplied. Using the FY25 shape as the only available shape proxy, the implied 2H FY25 contributions were NZ$50.0m of revenue and –NZ$21.4m of NPAT, so the second half is where both the upside and the loss exposure sits. The current half's record volumes and Brazil momentum are supportive directional signals, but the release does not provide a quantitative target against which to test conversion of HY momentum into FY26 outcomes.
What this release does support is that Brazil demand remains the operating engine and that US contribution is timing-deferred. What it does not support is any conclusion on whether 2H cash generation will recover the NZ$7.2m pre-lease FCF deficit.
Open questions
This briefing cannot assess 2H26 execution, US order pipeline conversion, or covenant headroom on the expanded debt facilities, none of which are quantified in the supplied materials.
Archive
Every published Annolyse briefing for this company appears here in reverse chronological order.
FY26 · Released 29 May 2026
Revenue grew 7.9% to a five-year high, but margin compression and rising leverage leave cash generation well below ArborGen's historical baseline.
HY26 · Released 26 November 2025
A NZ$5.0m working-capital build ahead of the seasonally heavy 2H drove OCF from +NZ$2.1m to -NZ$5.4m and required NZ$13.0m of new borrowings.
FY25 · Released 30 May 2025
Operating cash flow fell 76.9% to $2.7m and free cash flow swung NZ$10.2m to -$5.1m, below the historical NZ$0.9m–$5.1m range.
FY24 · Released 30 May 2024
NPAT looks 92.0% better on a tax swing while receivable days jumped 47 days and cash halved to $5.6m.
HY24 · Released 13 December 2023
A strong first half driven by record Brazil volumes is shadowed by a downward revision to US seedling sales in the heavier second half.
FY23 · Released 30 May 2023
PBT swung to US$0.9m and EBITDA rose 35%, but an unusually favourable working-capital release supplied most of the cash flow lift.
HY23 · Released 29 November 2022
Strong gross-margin expansion was overshadowed by negative operating cash flow in a seasonally light half, with NPAT optics distorted by the
FY22 · Released 30 May 2022
Continuing-ops revenue grew 11.2%, but a 156.7% effective tax rate flipped a PBT loss to US$1.7m NPAT while inventories built US$27.3m.
HY22 · Released 24 November 2021
Continuing-operations revenue lifted but a NZ$0.6m discontinued-operation gain is the only reason headline NPAT stayed positive at NZ$0.1m.
Get the next ArborGen Holdings result briefing and five-year history updates by email.